Technical Offer
Back to Search
Representation of the three FPR2 aptamers
Biomedical Innovation
P-077
New aptamer-based drugs for wound healing and inflammatory diseases
Abstract
CIEMAT, the Carlos III University of Madrid, the Foundation for Biomedical Research of the Ramón y Cajal University Hospital, Aptus Biotech, S.L. and the Health Research Institute Foundation of the Fundación Jiménez Díaz have developed a new targeted therapy based on DNA aptamers for wound healing, with the aim of improving efficacy and avoiding degradation in the proteolytic environment of chronic wounds. These aptamers have been generated against a receptor (FPR2) involved in the control of inflammation, so they have a great therapeutic potential against multiple inflammatory diseases.
What problems does it solve?
Chronic wounds are defined as those wounds that do not heal within an expected time frame. Chronic wounds constitute an important health problem from an epidemiological, economic and social point of view. One therapeutic strategy to promote healing is the topical administration of recombinant growth factors. However, these can be degraded by proteases in the wound bed, requiring repetitive applications and high doses that can result in toxicity and undesirable side effects.
Benefits
To overcome these problems, we have developed a targeted therapy based on the use of FPR2 aptamers, recognizing a receptor involved in the healing process. Due to their unique characteristics, aptamers present high affinity and specificity and show advantages in applicability (high stability and bioavailability and low immunogenicity) and in production (short term, low cost and minimal batch-to-batch variability). FPR2 aptamers have demonstrated their efficacy in a preclinical humanized model of wound healing, and they could also be beneficial in the treatment of other inflammatory diseases.
Potential customers
Pharmaceutical and cosmetics industry.
About the technology
• Technology in development phase (laboratory level).
• Technology patented.
• Collaboration requested: License agreement.